Medication info
Exmezole 20mg (Esomeprazole Magnesium Trihydrate)

Exmezole 20mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTablet
Ingredient · strength
Esomeprazole Magnesium Trihydrate›21.69mg / 1 tablet
Manufacturer / importer
Youngjin Pharmaceutical Co., Ltd.
Appearance
Pale pink colored round film-coated tablet
Packaging
28 tablets (14 tablets/Alu-Alu PTP*2)
Approval status
Active

MFDS item code 201404634 · Approved 2014.10.08 · Insurance code 642403920

Summary

Main use
Treatment and prevention of reflux disease, gastrointestinal disorders (such as ulcers and Helicobacter pylori infection), and Zollinger-Ellison syndrome
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water; do not chew or crush it. Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist may take it for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent episodes may be controlled by administering 20 mg once daily. In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling ongoing symptoms in patients at high risk of developing gastric and duodenal ulcers due to use of nonsteroidal anti-inflammatory drugs. Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg 2 times daily for 7 days. 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting longer than 4 weeks have not been conducted. Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4~8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The recommended initial dose is 40 mg 2 times daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with a dose of 80 ~ 160 mg per day. Doses above 80 mg per day should be divided into 2 doses. Administer 40 mg once daily for 4 weeks following intravenous treatment to prevent rebleeding due to gastric or duodenal ulcers. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. Elderly patients: No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and older — Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurrent symptoms may be controlled by administering 20 mg once daily. Adolescents aged 12 years and older — In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurrent symptoms in patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years: There is no experience with administration of this drug to children under 12 years.

Ingredients

Manufacturer
Youngjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment and prevention of reflux disease, gastrointestinal disorders (such as ulcers and Helicobacter pylori infection), and Zollinger-Ellison syndrome

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • Helicobacter pylori positive duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
  • rebleeding due to gastric ulcers
View approved original text

This medicine is used for the treatment of gastroesophageal reflux disease and erosive reflux esophagitis, and can also be used for long-term maintenance therapy to prevent recurrence in patients with esophagitis. It is also helpful for alleviating symptoms of gastroesophageal reflux disease in patients without esophagitis. It is utilized in the treatment and prevention of recurrence of duodenal ulcers and peptic ulcers in patients with Helicobacter pylori infection. It is effective for the short-term treatment of upper gastrointestinal symptoms associated with the use of non-steroidal anti-inflammatory drugs and for the treatment and prevention of gastric ulcers in patients requiring continued use. Additionally, it is used to treat Zollinger-Ellison syndrome and to prevent rebleeding from gastric or duodenal ulcers through maintenance therapy. This medicine plays an important role in improving various gastrointestinal disorders.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water; do not chew or crush it. Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist may take it for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent episodes may be controlled by administering 20 mg once daily. In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling ongoing symptoms in patients at high risk of developing gastric and duodenal ulcers due to use of nonsteroidal anti-inflammatory drugs. Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg 2 times daily for 7 days. 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting longer than 4 weeks have not been conducted. Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4~8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The recommended initial dose is 40 mg 2 times daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with a dose of 80 ~ 160 mg per day. Doses above 80 mg per day should be divided into 2 doses. Administer 40 mg once daily for 4 weeks following intravenous treatment to prevent rebleeding due to gastric or duodenal ulcers. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. Elderly patients: No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and older — Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurrent symptoms may be controlled by administering 20 mg once daily. Adolescents aged 12 years and older — In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurrent symptoms in patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years: There is no experience with administration of this drug to children under 12 years.

Precautions

This medicine should not be administered to certain patients. It should not be used by individuals who are allergic or hypersensitive to this medicine or its components, or to benzimidazole derivatives. It should also not be used in patients who are allergic to penicillin-based or macrolide antibiotics used in conjunction with eradication of Helicobacter pylori. Patients on certain cardiac medications or antiviral drugs, as well as nursing women, should not take this medicine. Patients with a history of myocardial infarction should also avoid this medicine. This medicine may have various side effects, so caution is required. Reports of abnormal reactions have included blood-related issues, allergic reactions, electrolyte imbalances, psychological changes, neurological symptoms, gastrointestinal problems, liver function abnormalities, skin reactions, and more. In particular, if muscle pain or weakness occurs, it may indicate a serious condition called rhabdomyolysis, and immediate medical attention should be sought. While this medicine reduces gastric acid secretion and aids in the treatment of gastrointestinal diseases, long-term use may increase the risk of infection due to bacterial overgrowth in the stomach. Additionally, prolonged use may increase the risk of fractures, so patients with osteoporosis should have their bone density checked regularly. Serum magnesium levels may drop after more than three months of use, necessitating periodic testing. This medicine has many drug interactions, so if you are taking other medications, be sure to consult your doctor or pharmacist. Caution is particularly necessary when used in conjunction with anticoagulants, anticonvulsants, certain antidepressants, antiviral drugs, and antibiotics. There is insufficient data regarding the safety of this medicine during pregnancy, so pregnant women should use it cautiously after consulting with their physician. Nursing women are advised not to take this medicine. In cases of overdose, special antidotes are not available, so treatment must be symptomatic and general management is necessary. It should be kept out of the reach of children. Additionally, transferring the medicine to another container can lead to a decrease in quality or cause accidents, so caution should be exercised.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reactions with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, hyperhidrosis, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, lethargy, pain, rigidity, peripheral edema, flushing, hypertension, tachycardia, thyroid gland enlargement, irritable bowel syndrome, worsening constipation, dyspepsia, dysphagia, gastrointestinal developmental disorders, upper abdominal pain, burping, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, black stools, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, lingual disorders, tongue edema, ulcerative stomatitis, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, spasms, fibromyalgia syndrome, hernia, polymyalgia rheumatica, loss of appetite, apathy, increased appetite, confusion, worsening depression, hypertonicity, sensory impairment, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremors, visual field defects, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, dysosmia, taste loss, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine is susceptible to air and moisture, so it must be stored in a tightly sealed container. The storage temperature should be maintained between 1 degree and 30 degrees Celsius, ideally at room temperature.

Appearance and packaging

Appearance

Pale pink colored round film-coated tablet

Package unit

28 tablets (14 tablets/Alu-Alu PTP*2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.